Discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell

Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field. 

Year Invested: 2013
Location: San Francisco, Calif.

Recent News

October 10, 2018
Nurix Therapeutics to Present at the 2018 BIO Investor Forum

May 8, 2018
Nurix Appoints Nancy Pryer, Ph.D., Chief Development Officer

December 6, 2016
Nurix Appoints Robert Tjian, Ph.D. of The Column Group to its Board of Directors

Read More News

Associated Team Members

Jeffrey Tong, Ph.D.
Venture Partner